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Summary 
Background: ATP-binding cassette (ABC) transporter and DNA excision repair 
proteins play a pivotal role in the mechanisms of drug resistance.  The aim of this 
study was to investigate the expression of ABC transporter and DNA excision repair 
proteins, and to elucidate the clinical significance of their expression in biopsy 
specimens from patients with small-cell lung cancer (SCLC).   
Methods: We investigated expression of the ABC transporter proteins, P-glycoprotein 
(Pgp), multidrug resistance associated-protein 1 (MRP1), MRP2, MRP3, and breast 
cancer resistance protein (BCRP), and the DNA excision repair proteins, excision repair 
cross-complementation group 1 (ERCC1) protein and breast cancer susceptibility gene 
1 (BRCA1) protein, in tumor biopsy specimens obtained before chemotherapy from 130 
SCLC patients who later received platinum-based combination chemotherapy, and 
investigated the relationship between their expression and both response and survival.  
Results: No significant associations were found between expression of Pgp, MRP1, 
MRP2, MRP3, ERCC1, or BRCA1 and either response or survival.  However, there 
was a significant association between BCRP expression and both response (p = 0.026) 
and progression-free survival (PFS; p = 0.0103). 
Conclusions: BCRP expression was significantly predictive of both response and 
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progression-free survival (PFS) in SCLC patients receiving chemotherapy.  These 
findings suggest that BCRP may play a crucial role in drug resistance mechanisms, and 


















Lung cancer is the leading cause of cancer-related deaths in many industrialized 
countries.  Although the proportion of patients with small-cell lung cancer (SCLC) has 
been decreasing, it still accounts for approximately 15% of all cases of lung cancer.  
SCLC is one of the most chemo-sensitive solid tumors, but the vast majority of patients 
eventually experience a relapse, and as a result the median survival time is 14-20 
months for limited disease (LD) and 7-10 months for extensive disease (ED)(1). 
Intrinsic or acquired drug resistance is considered to be a major factor limiting 
the effectiveness of chemotherapy.  Drug resistance by tumors occurs not only to a 
single cytotoxic agent, but in the form of cross-resistance to other cytotoxic agents, 
called multidrug resistance (MDR).  One of the major mechanisms of MDR is 
increased ability of tumor cells to actively efflux drugs, which leads to a decrease in 
intracellular drug accumulation, and the mechanism is mediated by ATP-dependent drug 
efflux pumps that are known as ATP-binding cassette (ABC) transporters(2, 3).  To 
date, at least 48 human ABC transporters have been identified, and they have been 
divided into seven subfamilies, ABC-A through ABC-G.  Five of them, P-glycoprotein 
(Pgp), multidrug resistance associated-protein 1 (MRP1), MRP2, MRP3, and breast 
cancer resistance protein (BCRP), have been most intensively investigated, and in vitro 
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studies have demonstrated associations between their expression and resistance to 
cytotoxic drugs commonly used in the treatment of SCLC, including etoposide, 
irinotecan, and topotecan(4). 
 Another important mechanism of drug resistance is increased repair of DNA 
damage mediated by the DNA excision repair gene.  Resistance to platinum is 
associated with increased removal of platinum-DNA adducts, and DNA excision repair 
plays a pivotal role in this process(5).  Nucleotide excision repair (NER) is a major 
mechanism for repairing platinum-DNA adducts, and it is now known that there are two 
pathways in NER: transcription-coupled NER (TC-NER) and global genomic NER 
(GG-NER)(5).  Among NER proteins, excision repair cross-complementation group 1 
(ERCC1) protein, which is involved in the GG-NER pathway, has been most intensively 
investigated.  Expression of ERCC1 has recently been shown to be a significant 
negative predictive factor for survival of non-small cell lung cancer (NSCLC) patients 
receiving cisplatin-based adjuvant chemotherapy(6).  On the other hand, the results of 
an in vitro study have suggested the superiority of TC-NER pathway, in which breast 
cancer susceptibility gene 1 (BRCA1) protein is involved, to GG-NER pathway in 
predicting platinum resistance(7).  Since platinum agents are considered to be key 
drugs in the treatment of SCLC as well as NSCLC(8-10), it is of great interest to 
 6 
determine whether there is an association between the expression of DNA excision 
repair genes and the effectiveness of platinum-based chemotherapy in SCLC patients.     
 In this retrospective study we investigated the immunohistochemical 
expression of the ABC transporter proteins, Pgp, MRP1, MRP2, MRP3, and BCRP, and 
the DNA excision repair proteins, ERCC1 protein and BRCA1 protein, in tumor biopsy 
specimens obtained before chemotherapy from 130 SCLC patients who later received 
platinum-based combination chemotherapy, and we investigated the relationship 












2. MATERIALS AND METHODS 
2.1. Subjects   
A total of 626 patients were diagnosed with SCLC at the National Cancer Center 
Hospital East between July 1992 and December 2005, and 578 of them received 
platinum-based combination chemotherapy as an initial treatment.  After excluding the 
246 patients who received thoracic radiotherapy and 2 patients who received surgery in 
order to eliminate the effects of treatment other than chemotherapy, the 191 patients of 
the remaining 330 patients diagnosed only cytologically, and therefore with no 
specimens available for analysis, and the nine patients whose specimens were 
unsuitable for immunohistochemistry.  In this study, we analyzed biopsy specimens 
from 130 patients consisting of 104 responders and 26 non-responders.  Institutional 
Review Board-approved informed consent was obtained from all patients. 
 
2.2. Clinical evaluation   
The classification system proposed by the Veterans’ Administration Lung Study Group 
was used to stage SCLC as limited disease (LD) or extensive disease (ED)(11).  LD is 
defined as disease confined to one hemithorax that can be encompassed within a single 
radiation field, and ED is defined as disease that extends beyond these confines.  
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Performance status (PS) was determined based on the Eastern Cooperative Oncology 
Group (ECOG) scale.  Patient response was evaluated by using the Response 
Evaluation Criteria in Solid Tumors (RECIST)(12). 
 
2.3. Immunohistochemistry   
Tissue blocks were cut into 4-μm sections and mounted on silane-coated slides 
(Matsunami, Tokyo, Japan).  The slides were then deparaffinized in xylene and 
dehydrated in a graded alcohol series.  For antigen retrieval, the slides for Pgp, MRP1, 
MRP2, BCRP, ERCC1, and BRCA1 were immersed in 10 mM citric buffer solution (pH 
6.0) at 120℃ for 20 min and the slides for MRP3 were immersed in 1 mM EDTA 
retrieval fluid (pH 8.0) at 95℃ for 20 min.  The slides were then allowed to cool for 1 
h at room temperature and washed in PBS.  Nonspecific binding was blocked by 
incubation with 2% BSA plus 0.1% NaN3 for 30 min, and after draining off the blocking 
solution, the slides were incubated overnight at 4℃ with the primary antibodies listed 
in Table 1.  Endogenous peroxidase was then blocked with 0.3% H2O2 in methanol for 
10 min, and after washing three times in PBS, the slides were incubated for 60 min with 
a labeled polymer En Vision+, peroxidase Mouse (DAKO, Glostrup, Denmark).  The 
chromogen used was 2% 3,3’-diaminobenzidine in 50 mM Tris buffer (pH 7.6) 
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containing 0.3% hydrogen, and the slides were counterstained with hematoxylin.  
Normal human liver tissue was used as a positive control for Pgp, MRP2, MRP3, and 
BCRP, normal human lung tissue for MRP1, normal human tonsil tissue for ERCC1, 
and breast cancer tissue human for BRCA1.  Negative controls for each antibody were 
prepared by using non-immune serum instead of the primary antibodies.  Membranous 
or cytoplasmic staining was evaluated for ABC transporter proteins(13), while nuclear 
staining was evaluated for DNA excision repair proteins(6, 14).  Staining of each 
antibody was considered positive if >10% of the tumor cells stained.  All of the slides 
were examined and scored independently by two observers (Y. K. and G. I.) without 
knowledge of the patients’ clinical data.  When judgments differed between two 
observers, they discussed it until an agreement was reached. 
 
2.4. Statistical analysis   
The significance of the relationship between immunohistochemical expression and 
clinical variables or response to chemotherapy was evaluated by using the χ2 test or 
Fisher’s exact test, as appropriate.  The logistic regression model was used for 
multivariate analysis of response.  Progression-free survival (PFS) was used as a 
clinical marker for duration of response to chemotherapy.  Overall survival (OS) was 
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measured from the start of chemotherapy to the date of death from any cause or the date 
patients were last known to be alive.  Survival rates were calculated by the 
Kaplan-Meier method, and the statistical significance of any differences in PFS and OS 
were evaluated by a log-rank test.  The Cox proportional hazards model was used for 
multivariate analysis of survival.  P values less than 0.05 were considered significant.  
All statistical analyses were performed using the statistical program StatView, Version 














3.1. Patient characteristics   
The patient characteristics are summarized in Table 2.  The median age of the patients 
was 67 years (range, 28-83 years).  More than 80% of the patients were male, and 
more than 80% had ED.  Despite excluding patients who had received thoracic 
radiotherapy or surgery, our study included 18 LD patients.  The major reasons for 
omitting thoracic radiotherapy in these LD patients were the presence of a malignant 
pleural effusion (9 patients) and interstitial pneumonia (5 patients).  PS was generally 
good; approximately 70% of the patients were PS 0 or 1.  All patients received 
chemotherapy containing etoposide, irinotecan, or topotecan.  The details of 
administered chemotherapy are shown in Table 3. 
 
3.2. Expression of ABC transporter and DNA excision repair proteins in SCLC 
The immunostaining of ABC transporter proteins was both membranous and 
cytoplasmic, whereas the immunostaining of the DNA excision repair proteins was 
mostly restricted to the nucleus.  Forty-two (33%) of the 130 tumors were Pgp-positive, 
29 (22%) were MRP1-positive, 25 (19%) were MRP2-positive, 9 (7%) were 
MRP3-positive, 48 (37%) were BCRP-positive, 36 (27%) were ERCC1-positive, and 
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109 (83%) were BRCA1-positive.  The relationships between expression of the ABC 
transporter and DNA excision repair proteins and the clinical variables are shown in 
Table 4.  BCRP expression was significantly greater in the PS 2-4 cases than in the PS 
0-1 cases (p = 0.0223).  There were no significant correlations between expression of 
Pgp, MRP1, MRP2, MRP3, ERCC1, or BRCA1 and the clinical variables. 
 
3.3. Association between expression of ABC transporter and DNA excision repair 
proteins and clinical outcome   
The relationships between clinical variables and response to chemotherapy and survival 
are shown in Table 5.  Response rate was not associated with any clinical variables, but 
PFS (p = 0.0199) and OS (p = 0.0159) were significantly associated with PS.  Table 6 
shows the associations between expression of ABC transporter and DNA excision repair 
proteins and response to chemotherapy and survival.  BCRP expression was 
significantly predictive of response to chemotherapy (p = 0.026), and MRP2 expression 
was marginally predictive (p = 0.0515).   
The median follow-up time was 8.3 years, and 119 patients had been dead until 
the time of analysis.  The results for survival showed that BCRP expression was 
significantly associated with PFS (p = 0.0103), but not with OS (p = 0.1427).  No 
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significant associations were observed between expression of Pgp, MRP1, MRP3, 
ERCC1, or BRCA1 and either response to chemotherapy or survival.  Representative 
immunohistochemical staining of BCRP and MRP2 is shown in Fig. 1. 
 
3.4. Multivariate analysis for response and survival   
A multivariate analysis revealed that BCRP expression was significantly predictive of 
response to chemotherapy (Table 7).  PFS was significantly associated with both PS (p 
= 0.0299) and BCRP expression (p = 0.0138), whereas OS was significantly associated 
with PS alone (p = 0.0295; Table 8).  The PFS and OS curves according to BCRP 











Although initial chemotherapy succeeds in 80% to 90% of SCLC patients, most patients 
eventually experience a relapse and their survival time is quite limited.  Unfortunately, 
little progress in the chemotherapy of SCLC has been made during the past 30 years(15).  
If drug resistance could be overcome, it would no doubt lead to an improved prognosis 
of this challenging disease, because drug resistance is considered a major obstacle to 
successful treatment.  In this study we investigated expression of the five ABC 
transporter proteins that are thought to be the most important in the drug resistance 
mechanisms of SCLC, and the results showed that BCRP expression alone was 
significantly associated with either response to chemotherapy or PFS.  Expression of 
BCRP was significantly correlated with impaired PS, but the multivariate analysis 
revealed BCRP to be an independent prognostic factor for PFS. 
BCRP, which is classified as ABCG2 and known as the mitoxantrone resistance 
gene (MXR) or ABC transporter in placenta (ABC-P), is expressed in a variety of 
normal tissues, with the highest levels having been found in the placenta, and lower 
levels in the liver, small intestine, brain, and ducts and lobules of the breast(2, 16).  
BCRP was initially isolated from doxorubicin-resistant breast cancer cell line MCF-7, 
and its overexpression was found to promote resistance to topoisomerase I inhibitors, 
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including irinotecan and topotecan(17).  We previously reported the finding that BCRP 
expression is a significant predictor of survival in advanced NSCLC(18), but to our 
knowledge no data have been reported regarding BCRP expression in SCLC.   
No significant association was found between the expression of other ABC 
transporter proteins and clinical outcome in the present study.  Some studies have 
shown a relationship between expression of Pgp or MRP1 and response or 
survival(19-23), however, their clinical usefulness as therapeutic targets is still obscure.  
In fact, two randomized phase III studies that incorporated modulators of Pgp and one 
phase II study of VX-710, an inhibitor of both Pgp and MRP1, failed to show any 
survival benefit in SCLC patients(24-26). 
In this study we also investigated the expression of the DNA excision repair 
proteins ERCC1 and BRCA1 in SCLC, but neither of them was related to response or 
survival.  Expression of DNA excision repair proteins has hardly ever been 
investigated in SCLC, and to our knowledge there has been only one study in regard to 
it.  In that study high expression of ERCC1 was associated with poor survival, but 
when the cases were grouped according to stage, a significant decrease in survival was 
observed only in the LD patients, and the correlation between ERCC1 expression and 
response was not mentioned(27).  By contrast, expression of DNA excision repair 
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proteins, especially ERCC1, has been intensively investigated in NSCLC recently, and 
expression of ERCC1 has been demonstrated to be related to platinum resistance in 
several studies(6, 28, 29).  We analyzed the ERCC1 expression also using the criterion 
by Olaussen et al. (6), but the results were similar and our conclusions did not change 
(data not shown).  BRCA1 expression was also demonstrated to be significantly 
associated with chemoresistance in one study(30).  However, in other studies no 
significant association was observed between expression of ERCC1 or BRCA1 and 
either response or survival(14, 31).  Their clinical significance in lung cancer including 
SCLC has yet to be determined, and further studies are awaited.  
The concept of "cancer stem cells", a very small fraction of the whole cell 
population repeating self-renewal continues to supply cancer-constitute cells, has 
recently gained wide acceptance.  Although the origin of cancer stem cells has not yet 
been elucidated, the idea that malignant transformation of a normal stem cell has been 
proposed(32).  Side population (SP) cells, defined by Hoechst 33342 dye exclusion in 
flow cytometry, are considered to be an enriched source of normal stem cells(33).  In 
addition, BCRP has been shown to be a molecular determinant of the SP phenotype, and 
it can be used as a marker for stem cell selection(34).  In a recent study, SP cells 
isolated from lung cancer displayed elevated expression of BCRP and showed resistance 
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to multiple chemotherapeutic agents(35).  These findings indicate that it may be 
possible to use BCRP as a marker of cancer stem cells in certain types of lung cancer. 
In conclusion, the results of the present study indicated that 
immunohistochemical expression of BCRP is significantly associated with response and 
PFS in SCLC patients treated with platinum-based chemotherapy.  Our results should 
be tested in LD patients who received thoracic radiotherapy, and it is also desirable that 
our results will be validated in other methods, such as mRNA expression analysis.  
Although confirmatory studies are needed, BCRP may be an ideal therapeutic target for 
SCLC.  A variety of BCRP inhibitors have already been identified(36-39).  Clinical 
trials of combination of these agents with conventional chemotherapy might be 
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 Representative cases of positive immunostaining for BCRP (A, ×100; B, ×400) and 
MRP2 (C, ×100; D, ×400).  BCRP and MRP2 in the apical membrane of the 
bronchial layer have been immunostained as a positive control. 
 
Fig. 2  
 Progression-free survival curves (A) and overall survival curves (B) for 130 SCLC 
patients, according to breast cancer resistance protein (BCRP) expression.  
 
Antibody Clone Pretreatment Dilution City/nation Source
Pgp (mono) JSB-1 Autoclave 1:20 Newcastle/United Kingdom Novocastra
MRP1 (mono) MRPm6 Autoclave 1:50 Uden/Netherlands Sanbio
MRP2 (mono) M2III-6 Autoclave 1:20 Uden/Netherlands Sanbio
MRP3 (mono) DTX1 Autoclave   1:100 Newcastle/United Kingdom Novocastra
BCRP (mono) BXP21 Autoclave 1:20 Uden/Netherlands Sanbio
ERCC1 (mono) 8F1 Autoclave   1:100 Warm Springs/United States Lab vision
BRCA1 (mono) MS110 Microwave   1:100 San Diego/United States Carbiochem
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Table 1  Panel of primary antibodies
   Characteristics No. of patients (%)
   Age
      Median 67
      Range 28-83
   Gender
      Male 108 (83)
      Female   22 (17)
   Disease extent
      LD   18 (14)
      ED 112 (86)
   Performance status
      0   2 (2)
      1   93 (71)
      2   25 (19)
      3   8 (6)
      4   2 (2)
   Chemotherapy regimen
      CE  36 (28)
      PE  35 (27)
      PI  25 (19)
      CODE  18 (14)
      CAV / PE  7 (5)
      PEI  7 (5)




Cisplatin+Etoposide+Irinotecan ; PT, Cisplatin+Topotecan
Table 2  Patient characteristics (n = 130)
LD, limited disease ; ED, extensive disease;
CE, Carboplatin+Etoposide; PE, Cisplatin+Etoposide;
PI, Cisplatin+Irinotecan; CODE, Cisplatin+Vincristine
      CE Carboplatin AUC 6 day 1 q3w
Etoposide 100 mg/m
2 day 1-3
      PE Cisplatin 60 mg/m
2 day 1 q3w
Etoposide 100 mg/m
2 day 1-3
      PI Cisplatin 60 mg/m
2 day 1 q4w
Irinotecan 60 mg/m
2 day 1,8,15
      CODE Cisplatin 25 mg/m
2 day 1 (1,2,3,4,5,6,7,8,9 week) weekly
Vincristine 1 mg/m
2 day 1 (2,4,6,8 week)
Doxorubicin 40 mg/m
2 day 1 (1,3,5,7 week)
Etoposide 80 mg/m
2 day 1-3 (1,3,5,7 week)
      CAV / PE Cyclophosphamide 800 mg/m









      PEI Cisplatin 25 mg/m
2 day 1 (1,2,3,4,5,6,7,8,9 week) weekly
Etoposide 60 mg/m
2 day 1-3 (1,3,5,7 week)
Irinotecan 90 mg/m
2 day 1 (2,4,6,8 week)
      PT Cisplatin 60 mg/m




regimen dosage of each agent schedule
AUC, area under the curve
4.5 (4-5)









n Pgp-positive (%) MRP1-positive (%) MRP2-positive (%) MRP3-positive (%) BCRP-positive (%) ERCC1-positive (%) BRCA1-positive (%)
    Total 130 42 (33) 29 (22) 25 (19) 9 (7) 48 (37) 36 (27) 109 (83)
    Age
       <70 83 29 (35) 16 (19) 15 (18) 5 (6) 29 (35) 24 (29) 70 (84)
       ≥70 47 13 (28) 13 (28) 10 (21) 4 (9) 19 (40) 12 (26) 39 (83)
    Gender
       Male 108 36 (33) 23 (21) 19 (18) 9 (8) 41 (38) 30 (28) 93 (86)
       Female 22   6 (27)   6 (27)   6 (27) 0 (0)   7 (32)   6 (27) 16 (73)
    Disease extent
       LD 18   8 (44)   3 (17)   6 (33)   3 (17)   8 (44)   4 (22) 16 (89)
       ED 112 34 (30) 26 (23) 19 (17) 6 (5) 40 (36) 32 (29) 93 (83)
    PS
       0-1 95 33 (35) 20 (21) 21 (22) 8 (8) 29 (31)a 27 (28) 80 (84)
       2-4 35   9 (26)   9 (26)   4 (11) 1 (3) 19 (54)   9 (26) 29 (83)
a p = 0.0223
27
ABC, ATP-binding cassette; Pgp, P-glycoprotein; MRP, multidrug resistance protein; BCRP, breast cancer resistance protein; ERCC, excision repair cross-complementation group;
BRCA, breast cancer susceptibility gene; LD, limited disease; ED, extensive disease; PS, performance status
Table 4  Relationship between clinical variables and expression of ABC transporter and DNA excision repair proteins
n Response rate (%) p PFS (mo) p MST (mo) p
    Total 130 79 5.2 9.0
    Age
       <70 83 80 >0.9999 5.1 0.1296 9.4 0.3493
       ≥70 47 81 5.4 10.9
    Gender
       Male 108 81 0.7715 5.1 0.5496 9.4 0.6528
       Female 22 77 5.7 13.2
    Disease extent
       LD 18 67 0.2277 5.6 0.4838 9.4 0.8856
       ED 112 82 5.2 10.4
    PS
       0-1 95 82 0.4584 5.5 0.0199* 10.8 0.0159*
       2-4 35 74 4.2 8.1
LD, limited disease; ED, extensive disease; PS, performance status; PFS, progression-free survival; MST, median survival time
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Table 5  Summary of relationship between clinical variables and response to chemotherapy and survival
n Response rate (%) p PFS (mo) p MST (mo) p
    Pgp
       Positive 42 83 0.6730 5.5 0.7257 10.5 0.3006
       Negative 88 78 5.1 9.9
    MRP1
       Positive 29 90 0.1902 5.3 0.8141 11.0 0.2249
       Negative 101 77 5.2 9.4
    MRP2
       Positive 25 64 0.0515 5.6 0.5832 12.6 0.1261
       Negative 105 84 5.2 9.3
    MRP3
       Positive 9 78 >0.9999 5.2 0.3181 11.9 0.1326
       Negative 121 80 5.3 9.4
    BCRP
       Positive 48 69  0.0260* 4.0  0.0103* 9.1 0.1427
       Negative 82 87 5.6 10.6
    ERCC1
       Positive 36 89 0.1452 5.4 0.5383 11.9 0.6250
       Negative 94 77 4.3 9.3
    BRCA1
       Positive 109 79 0.5666 5.3 0.8404 10.5 0.4611
       Negative 21 86 4.7 8.1
29
ABC, ATP-binding cassette; Pgp, P-glycoprotein; MRP, multidrug resistance protein; BCRP, breast cancer resistance protein; ERCC, excision repair cross-
complementation group; BRCA, breast cancer susceptibility gene; PFS, progression-free survival; MST, median survival time
Table 6  Association between expression of ABC transporter and DNA excision repair proteins and response to chemotherapy and survival (n = 130)
Variables Category Risk ratio 95% CI p
Age <70 vs. ≥70 0.701 0.263-1.869 0.4776
Gender Female vs. Male 0.857 0.258-2.848 0.8014
Disease extent LD vs. ED 1.81 0.545-6.018 0.3329
PS 0-1 vs. 2-4 1.315 0.471-3.676 0.6013
MRP2 (-) vs. (+) 2.238 0.779-6.429 0.1346
BCRP (-) vs. (+) 2.804 1.103-7.128  0.0303*
30
Table 7  Multivariate analysis for response (n = 130)
Variables Category Risk ratio 95% CI p
Age <70 vs. ≥70 0.691 0.464-1.028 0.0682
Gender Female vs. Male 1.062 0.650-1.733 0.8105
Disease extent LD vs. ED 0.87 0.501-1.512 0.6251
PS 0-1 vs. 2-4 1.592 1.046-2.424  0.0299*
BCRP (-) vs. (+) 1.614 1.102-2.363  0.0138*
Variables Category Risk ratio 95% CI p
Age <70 vs. ≥70 0.832 0.565-1.224 0.3496
Gender Female vs. Male 1.067 0.658-1.729 0.7936
Disease extent LD vs. ED 1.131 0.673-1.901 0.6430
PS 0-1 vs. 2-4 1.588 1.047-2.407  0.0295*
BCRP (-) vs. (+) 1.235 0.831-1.833 0.2962
31
LD, limited disease; ED, extensive disease; PS, performance status; BCRP, breast cancer resistance protein
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